XXXVIII
Congreso de la Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica
101
43 Straub DA, , Minocchieri S , Mo-
eller A, Hamacher, Wildhaber JH.
The effect of montelukast on exha-
led nitric oxide and lung function in
asthmatic children 2 to 5 years old.
Chest 2005 ; 127 : 509 -12
44.
Pelkonen AS, Malmstron K, Sarna
S, Kajosaari M, Klemola T, Malm-
berg P, Makela MJ. The effect of
momtelukast on respiratory symp-
toms and lung function in wheezy
infants. Eur Respir J 2013; 41: 664-
670
45.
Robertson CF, Price D, Henry R, Me-
llis C, Glasgow N et al. Short course
montelukast for intermitent asthma
in children with recurrent wheezing.
N Engl J Med 2011; 365: 1990- 2001
46.
Valovirta E, Boza ML, Robertson CF,
Verbruggen N, Smugar SS, Nelsen
LM et al. Intermittent o daily mon-
telukast versus placebo for episo-
dic asthma in children. Ann Allergy
Asthma Immunol 2011; 106: 518-526
47.
RD Real Decreto 1015/2009, de 19 de
Junio, por el que se regula la dis-
ponibilidad de medicamentos en
situaciones especiales. BOE 2009.
60904-60913
48.
Tasche MJ, van der Wouden JC, Ui-
jen JH, Ponsioen BP, Bernsen RM,
Suijlekom-Smit LW et al. Rando-
mised placebo-controlled trial of
inhaled sodium cromoglycate in
1-4-year-old children with modera-
te asthma. Lancet 1997; 350: 1060-
1064.
49.
Nielsen KG, Bisgaard H. Bronchodi-
latacion and bronchoprotection in
asthmatics preeschol children from
formoterol a administered by mec-
hanically actuated dry powdes in-
halar and spacer. Am J Respir Crti
Care Med 2001 ; 164; 256-59
50. Sekhsaria S, Alam M, Sait T, Starr
B, Parekh M. Efficacy and safety of
inhaled corticosteroids in combina-
roids in preschool children at high
risk for asthma. N Engl J Med 2006;
354: 1985-1997.
36.
Bisgaard H, Hermansen MN, Lo-
land L, Halkjaer LB, Buchvald F. In-
termittent inhaled corticosteroids
in infants with episodic wheezing.
N Engl J Med 2006; 354: 1998-2005.
37.
Murray CS, Woodcock A, Langley
SJ, Morris J, Custovic A. Secondary
prevention of asthma by the use of
inhaled Fluticasone propionate in
Wheezy infants (IFWIN): double –
blind, randomised, controlled stu-
dy. Lancet 2006; 368: 754-762
38.
Anhoj J, Bisgaard AM, Bisgaard H.
Systemic activity of ihaled steroids
in 1 – to 3 year-old children with as-
thma. Pediatrics 2002; 109:E40
39.
Reid A, Murphy C, Steen HJ, McGo-
vern V, Shields MD, Linear growth
of very young asthmatic children
treatment with high-dose nebulized
budesonide. Acta Paediatr 1996; 85:
421.24
40.
Bisgaard H, Zielen S, Garcia – Gar-
cia ML, Johnston SL, Gilles L, Men-
ten J. Montelukast reduces asthma
exacerbations in 2 – to 5 – year – old
children with intermittent asthma.
Am J Respir Crit Care Med 2005 ;
171: 315 – 2242.
41.
Knorr B, Farnchi LM, Bisgaard H,
Vermeulen JH, LeSouef P, Santane-
llo N. Montelukast, a leucotriene re-
ceptor antagonist fort he treatment
of persistent asthma in children
aged 2 to 5 years. Pediatrics 2001;
108: e48
42.
Straub DA, Moeller A, Minocchieri
S, Hamacher J, Sennhauser FH, Hall
GL et al. The effect of montelukast
on lung function and exhaled nitric
oxide in infants with early childho-
od asthma. Eur Respir J 2005; 25:
289-294.
